Significant Ownership of BAKER BROS. ADVISORS LP

Signature - Title
/s/ Scott L. Lessing - Scott L. Lessing / President, By: Baker Bros. Advisors (GP) LLC, its general partner
Location
New York, NY
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by BAKER BROS. ADVISORS LP.

Follow Filing Activity

Follow BAKER BROS. ADVISORS LP and return when a new Schedule 13D/G filing appears.

This tracks SEC filing changes for this page using existing product update flows.

Sign up to follow filing activity

Sponsored

Significant Ownership of BAKER BROS. ADVISORS LP

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
KOD Kodiak Sciences Inc. Common Stock, $0.0001 par value per share 33% $416,802,847 20,067,542 Baker Bros. Advisors LP 18 Dec 2025
ACAD ACADIA Pharmaceuticals Inc. Common Stock, $0.0001 par value per share 25% $1,162,886,859 43,294,373 Julian C. Baker 24 Feb 2026
PRLD Prelude Therapeutics Inc Common Stock, $0.0001 par value per share 24% $8,010,575 10,269,968 Baker Bros. Advisors LP 12 Jun 2025
CELC Celcuity Inc. Common Stock, $0.001 par value per share 20% $998,822,957 +$191,489,480 9,582,874 +24% Baker Bros. Advisors LP 20 Mar 2026
SERA Sera Prognostics, Inc. Class A Common Stock, $0.0001 par value per share 16% $18,418,870 5,498,170 Baker Bros. Advisors LP 12 Feb 2025
INCY Incyte Corp Common Stock, $0.001 par value per share 16% $3,228,403,720 31,213,417 Felix J. Baker 06 Feb 2026
REPL Replimune Group, Inc. Common Stock, $0.001 par value per share 14% $99,960,291 11,045,336 Baker Bros. Advisors LP 07 Mar 2025
KYMR Kymera Therapeutics, Inc. Common Stock, $0.0001 par value per share 11% $551,236,913 +$127,711,627 8,676,797 +30% Baker Bros. Advisors LP 09 Dec 2025
DBVT DBV Technologies S.A. Ordinary shares, nominal value 0.10 euro per share 10% $490,489,821 +$40,190,632 25,586,190 +8.9% Baker Bros. Advisors LP 12 Jan 2026
KALA KALA BIO, Inc. Common Stock, $0.001 par value per share 10% $1,762,934 +$1,308,631 2,890,055 +288% Baker Bros. Advisors LP 31 Dec 2025
IMTX Immatics N.V. Ordinary Shares, nominal value EUR 0.01 per share 10% $103,041,681 +$16,402,644 12,094,094 +19% Baker Bros. Advisors LP 30 Sep 2025
RYTM Rhythm Pharmaceuticals, Inc. Common Stock, par value $0.001 per share 8.9% $360,984,750 5,604,483 Baker Bros. Advisors LP 31 Mar 2025
NRIX Nurix Therapeutics, Inc. Common Stock, par value $0.001 per share 7.2% $138,364,566 7,527,996 Baker Bros. Advisors LP 31 Dec 2025
NGNE Neurogene Inc. Common Stock, par value $0.000001 per share 7% $21,254,360 -$10,597,328 991,804 -33% Julian C. Baker 30 Jun 2025
EWTX Edgewise Therapeutics, Inc. Common Stock, par value $0.0001 per share 6.9% $95,196,398 7,305,940 Baker Bros. Advisors LP 30 Jun 2025
GLUE Monte Rosa Therapeutics, Inc. Common Stock, par value $0.0001 per share 6.7% $104,254,207 4,345,736 Baker Bros. Advisors LP 31 Dec 2025
ALKS Alkermes plc. Ordinary Shares, $0.01 per share 6.1% $280,143,231 10,012,267 Baker Bros. Advisors LP 31 Dec 2025
STOK Stoke Therapeutics, Inc. Common Stock, par value $0.0001 per share 5.8% $105,906,763 3,336,697 Baker Bros. Advisors LP 31 Dec 2025
GRAL GRAIL, Inc. Common Stock, par value $0.001 per share 5.3% $208,741,833 2,085,333 Baker Bros. Advisors LP 31 Dec 2025
CERS Cerus Corporation Common Stock, par value $0.001 per share 5.2% $15,944,852 -$4,572,043 10,028,209 -22% Julian C. Baker 30 Sep 2025
CADL Candel Therapeutics, Inc. Common Stock, par value $0.01 per share 5% $11,882,723 -$2,550,075 2,455,108 -18% Baker Bros. Advisors LP 31 Mar 2025
RVMD Revolution Medicines, Inc. Common Stock, par value $0.0001 per share 4.9% $971,159,717 +$9,283,443 9,455,357 +0.97% Baker Bros. Advisors LP 31 Dec 2025
BMEA Biomea Fusion, Inc. Common Stock, par value $0.0001 per share 4% $3,194,378 1,451,990 Baker Bros. Advisors LP 31 Dec 2024
IGMS IGM Biosciences, Inc. Common Stock, $0.01 par value per share 0% $0 0 Baker Bros. Advisors LP 14 Aug 2025

Schedules 13D/G Reported by BAKER BROS. ADVISORS LP:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Sponsored